$JANX News

Janux Therapeutics (JANX), What Is Drawing Fresh Attention Now?

Janux Therapeutics (JANX) Stock May Look Overvalued After Its 110% Run

Is Janux’s Dual JANX013–JANX007 Trial Advancing a Durable Precision Oncology Platform for JANX?

Janux Therapeutics (JANX) Advances Prostate Cancer Trial While Valuation Still Looks Pricey

Janux Therapeutics: It's Too Early To Tell If Prostate Cancer Program Can Succeed

Janux Therapeutics, Inc. (JANX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference - Slideshow

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013

Janux Therapeutics Doses First Patient In The Phase 1 Clinical Trial For JANX013, Its PSMA-Targeted Tumor-Activated CD28 Co-Stimulatory Bispecific, In Patients With Metastatic Castration-Resistant Prostate Cancer

Wolfe Research Upgrades Janux Therapeutics to Outperform, Announces $23 Price Target

Janux Therapeutics (JANX) Is Up 7.1% After Reporting Narrower Net Losses And Improved Earnings Profile

Guggenheim Maintains Buy on Janux Therapeutics, Lowers Price Target to $55

Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates

Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

Janux Therapeutics Q2 EPS $(0.35) Beats $(0.38) Estimate, Sales $10.267M Miss $16.493M Estimate

Truist Securities Assumes Janux Therapeutics at Buy, Lowers Price Target of $26

Wall Street Analysts Predict a 155.82% Upside in Janux Therapeutics (JANX): Here's What You Should Know

Piper Sandler Maintains Overweight on Janux Therapeutics, Lowers Price Target to $26

Wedbush Maintains Outperform on Janux Therapeutics, Lowers Price Target to $36

Guggenheim Maintains Buy on Janux Therapeutics, Lowers Price Target to $58

Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Lags Revenue Estimates